3PBIOVIAN, a contract development and manufacturing organization (CDMO), has successfully secured French CIR (Crédit d’Impôt Recherche) certification for its facilities located in Turku, Finland, and Pamplona, Spain. This certification is valid until 2027 and allows French companies collaborating on eligible research and development (R&D) projects to benefit from significant tax incentives.
The CIR certification confirms that 3PBIOVIAN’s services are recognized as eligible for R&D activities undertaken by French partners. This framework aims to enhance international research collaborations by providing financial relief for companies that engage in qualifying projects with 3PBIOVIAN.
Details of the Certification
The certification marks a first for the Turku site, while the Pamplona location has successfully completed its recertification process, having previously held this designation. With both sites now holding valid CIR certification, 3PBIOVIAN is poised to strengthen its offerings in the biotechnology sector.
3PBIOVIAN emphasized that this achievement reinforces its commitment to delivering comprehensive solutions encompassing both development and contract manufacturing for recombinant proteins and advanced therapies. The company aims to support clients in their operational excellence while advancing biotechnological innovation.
In a statement regarding the certification, 3PBIOVIAN highlighted its dedication to providing high-value R&D services. The company believes that fostering international collaboration is essential for advancing scientific and technological projects that ultimately benefit patients.
With the CIR certification now in place, 3PBIOVIAN is better equipped to attract partnerships with French companies seeking to leverage its expertise in R&D. The certification not only enhances the company’s reputation but also enables it to contribute significantly to the growing global landscape of biotechnology and pharmaceuticals.
